This leads to poor planning and resource allocation to diabetes programmes – such as an inability to quantify demand for insulin and diabetes supplies – and results in poor quality care for diabetes patients, as well as exacerbating common comorbidities such as HIV and tuberculosis [4]. This evidence concerns the gene INS and diabetes mellitus.